Early two-dose measles vaccination schedule in Guinea-Bissau: good protection and coverage in infancy
- PMID: 10342702
- DOI: 10.1093/ije/28.2.347
Early two-dose measles vaccination schedule in Guinea-Bissau: good protection and coverage in infancy
Abstract
Background: Previous studies from Africa have suggested that there is little benefit to be gained from early two-dose measles vaccination schedules. Two-dose schedules have been associated with no improvement in coverage due to immunization of the same individuals on both occasions, low return rate, high refusal rate, low vaccine efficacy, and fear of blunting of the antibody response. Because of the poor results achieved previously with two-dose measles vaccination schedules, we studied patterns of participation, reasons for non-participation, vaccination coverage and relative efficacy of a one-dose versus a two-dose schedule in connection with the implementation of an early two-dose trial in Guinea-Bissau.
Methods: Children born from September 1994 to January 1996 were randomized into two groups receiving either two doses of measles vaccine at 6 and 9 months or one dose of inactivated polio vaccine (IPV) at 6 months and measles vaccine at 9 months.
Results: At 6 months of age 86% (1869/2181) of the children participated, and at 9 months of age participation was 87% (1775/2035). The return rate for obtaining a second dose of vaccine was 93% (1647/1773). The main reason for not participating was travelling (78%). Around 50% of those who did not take part in one vaccination took part in the other. When only children participating the first time they were called for a measles vaccination were included, the measles vaccination coverage in the one-dose group was 59% versus 80% in the two-dose group, i.e. a 50% reduction in the risk of not being vaccinated (relative risk [RR] 0.50; confidence interval [CI]: 0.43-0.57). Few measles cases have occurred in the study area since the implementation of the trial making precise estimation of the relative efficacy of the two vaccine strategies difficult, but all seven clinically diagnosed measles cases occurred in the one-dose group making the relative efficacy for the two-dose group compared with the one-dose group 100% (95% CI: 35%-100%; two-tailed P = 0.016). When including maternal reports, the relative efficacy was 90% (95% exact confidence interval; two-tailed P = 25%-97%, P = 0.022).
Conclusion: In this study of a two-dose measles immunization schedule at 6 and 9 months of age there was no sign of low participation or poor return rates. The risk of not being vaccinated was lower in the two-dose group than in the one-dose group, and the relative efficacy of a two-dose versus a one-dose schedule was high. Although our results were obtained within a trial where dedicated personnel informed every participant personally about the study, we believe our results indicate that with thorough information about the population it may be possible to achieve a higher coverage with a two-dose measles vaccination schedule than a one-dose schedule. A two-dose schedule may be a feasible way to resolve the problems of low coverage and severe measles infection among infants.
PIP: Early 2-dose measles vaccination schedules in Africa have been associated with no improvement in coverage due to immunization of the same individuals on both occasions, low return rate, high refusal rate, low vaccine efficacy, and fear of blunting the antibody response. Findings are presented from the study of patterns of vaccination participation, reasons for nonparticipation, vaccination coverage, and the relative efficacy of a 1-dose versus 2-dose schedule in connection with the implementation of an early 2-dose trial in Guinea-Bissau. Children born from September 1994 to January 1996 were randomized into 2 groups receiving either 2 doses of measles vaccine at 6 and 9 months or 1 dose of inactivated polio vaccine (IPV) at age 6 months and measles vaccine at 9 months. 93% of children returned to receive a second dose of vaccine, with the main reason for nonparticipation being the need to travel. About half of the children who did not participate in 1 vaccination took part in the other. There was no sign of low participation or poor return rates in this study of a 2-dose measles immunization schedule at ages 6 and 9 months. The risk of not being vaccinated was lower in the 2-dose group than in the 1-dose group, and the relative efficacy of a 2-dose versus 1-dose schedule was high. These results indicate that with thorough information about the population it may be possible to achieve higher coverage with a 2-dose measles vaccination schedule than with a 1-dose schedule. A 2-dose schedule may be a feasible way of resolving the problems of low coverage and severe measles infection among infants.
Similar articles
-
Reduced childhood mortality after standard measles vaccination at 4-8 months compared with 9-11 months of age.BMJ. 1993 Nov 20;307(6915):1308-11. doi: 10.1136/bmj.307.6915.1308. BMJ. 1993. PMID: 8257884 Free PMC article.
-
Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, west Africa.Lancet. 1997 Jul 12;350(9071):101-5. doi: 10.1016/S0140-6736(96)12019-5. Lancet. 1997. PMID: 9228962 Clinical Trial.
-
Trial of high-dose Edmonston-Zagreb measles vaccine in Guinea-Bissau: protective efficacy.Lancet. 1988 Oct 8;2(8615):809-11. doi: 10.1016/s0140-6736(88)92780-8. Lancet. 1988. PMID: 2902263 Clinical Trial.
-
Two-dose measles vaccination schedules.Bull World Health Organ. 1993;71(3-4):421-8. Bull World Health Organ. 1993. PMID: 8324862 Free PMC article. Review.
-
Measles control in developing and developed countries: the case for a two-dose policy.Bull World Health Organ. 1993;71(1):93-103. Bull World Health Organ. 1993. PMID: 8440043 Free PMC article. Review.
Cited by
-
Exploring spatial variations and the individual and contextual factors of uptake of measles-containing second dose vaccine among children aged 24 to 35 months in Ethiopia.PLoS One. 2023 Jan 4;18(1):e0280083. doi: 10.1371/journal.pone.0280083. eCollection 2023. PLoS One. 2023. PMID: 36598928 Free PMC article.
-
The optimal age of measles immunisation in low-income countries: a secondary analysis of the assumptions underlying the current policy.BMJ Open. 2012 Jul 19;2(4):e000761. doi: 10.1136/bmjopen-2011-000761. Print 2012. BMJ Open. 2012. PMID: 22815465 Free PMC article.
-
Modelling the first dose of measles vaccination: the role of maternal immunity, demographic factors, and delivery systems.Epidemiol Infect. 2011 Feb;139(2):265-74. doi: 10.1017/S0950268810001329. Epub 2010 Jun 7. Epidemiol Infect. 2011. PMID: 20525415 Free PMC article.
-
Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: randomised controlled trial.BMJ. 2010 Nov 30;341:c6495. doi: 10.1136/bmj.c6495. BMJ. 2010. PMID: 21118875 Free PMC article. Clinical Trial.
-
Immunological impact of an additional early measles vaccine in Gambian children: responses to a boost at 3 years.Vaccine. 2012 Mar 28;30(15):2543-50. doi: 10.1016/j.vaccine.2012.01.083. Epub 2012 Feb 5. Vaccine. 2012. PMID: 22314136 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical